Browse a selection of ImaginAb press and news below.
ImaginAb and ARTMS Announce Strategic Partnership for Innovative Manufacture of 89Zr CD8 ImmunoPET Agent
Collaboration to explore novel radiochemistry manufacture of ImaginAb’s Phase II clinical asset.
Under the terms of the agreement, ImaginAb’s CD8 ImmunoPET technology will be used in AstraZeneca’s clinical trials in North America and Europe to facilitate clinical development of AstraZeneca’s novel immunotherapies and to advance the clinical utility of ImaginAb’s CD8 ImmunoPET.
ImaginAb, Inc., a clinical-stage immuno-oncology imaging company, announces it has initiated its Phase II clinical trial of its lead product, CD8 tracer 89Zr-Df-IAB22M2C, at Penn Medicine in Philadelphia, PA. Penn Medicine is one of the world’s leading academic medical centers.
ImaginAb signs multi-party collaboration agreement with three global pharmaceutical companies to help further develop company’s CD8 ImmunoPET technology
ImaginAb, Inc., signs multi-party collaboration agreement with AstraZeneca (LSE/STO/NYSE: AZN), Pfizer Inc. (NYSE: PFE) and Takeda Pharmaceutical Company Limited (Takeda) focused on furthering the clinical development of ImaginAb’s CD8 ImmunoPET technology.
ImaginAb, Inc., a clinical-stage immuno-oncology imaging company, today announces that its Chief Executive Officer, Ian Wilson, will present an update on ImaginAb and progress achieved with the CD8 ImmunoPET minibody at the upcoming Innovation Showcase 2019 on Monday, October 14, 2019, at The Lundquist Institute (formerly LA BioMed),1124 West Carson Street, Torrance, CA.
ImaginAb Announces Publication of Data on First-In-Human Imaging in Patients with Solid Malignancies in The Journal of Nuclear Medicine
ImaginAb Inc., a clinical-stage immuno-oncology imaging company, today announces publication of its data in leading peer-reviewed medical radiology publication, The Journal of Nuclear Medicine (JNM). The paper entitled "First-in-human imaging with 89Zr-Df-IAB22M2C anti-CD8 minibody in patients with solid malignancies: preliminary pharmacokinetics, biodistribution, and lesion targeting[i]" reports the results from a first in-vivo clinical study to assess the safety, tolerability, and efficacy of ImaginAb’s lead product, CD8 tracer, 89Zr-Df-IAB22M2C, in visualizing the immune system.